Bioporto A/s · OMXCOP:BIOPOR
Bioporto A/s — Q1 2026 Earnings Presentation
13 slides from Bioporto A/s's earnings presentation, May 21, 2026
Slide 1: Q1 2026 Trading Update
BioPorto Q1 2026 Trading Update Carsten Buhl, CEO & Klaus Juhl Wulff, CFO May 21, 2026 CONFIDENTIAL | © Copyright BioPorto |
Slide 2: Forward-looking statements
Forward-looking statements References herein to this presentation shall mean and include this document, any oral presentation accompanying this document provided by BioPorto A/S (the “Company” or “BioPorto”), and any further information that may be made available in connection with the subject matte
Slide 3: Invest in AKI Diagnostic - Invest in BioPorto
Invest in AKI Diagnostic - Invest in BioPorto Early detection of AKI (Acute Kidney Injury) represents a major unmet need1 BioPorto’s ProNephro AKI (NGAL) is the first FDA-cleared test for pediatric AKI assessment Defined pathway for FDA approval and commercial launch of ProNephro AKI (NGAL) for adul
Slide 4: The "Forward" Strategic Plan
The ”Forward” Strategic Plan Focus on execution of Market Access & Commercialization to transform kidney care Aspirations* 1 Adoption +60 US Hospitals 1H 2028 Cash + Validation Study flow Positive 2026 High +100 Global Hospitals FY 2028 Revenue 2 Growth + Adult Indication 2027 135-185m DKK +170 Glob
Slide 5: Highlights of Q1 2026
Highlights of Q1 2026 NGAL revenue continue solid growth, with year-over-year growth of 33% to DKK 6 million (48% growth in constant exchange rate) BioPorto submitted pre-submission to the FDA on its ProNephro AKI (NGAL) study for adult use. Feedback from the FDA expected in June 2026 KDIGO guidelin
Slide 6: Update; Market Access – Adult Clinical Study
Update; Market Access – Adult Clinical Study Pre-sub submitted to the FDA end of March 2026 Study designed to identifying adult FDA Clearance of Adult clinical study FDA Clearance patients at risk of developing will open an addressable market expected end 2027 moderate-to-severe acute kidney injury
Slide 7: Update; Market Access – KDIGO Guideline
Update; Market Access – KDIGO* Guideline A need for earlier, more precise diagnosis by combining functional & structural tests Draft end March26 … BioPorto input early May26… What it means … • Clear distinction between functional vs. structural BioPorto’s input to KDIGO AKI strengthens the • Improve
Slide 8: Preventing AKI progression cuts healthcare costs
Preventing AKI progression cuts healthcare costs Intervene early: avoid costly AKI progression AKI is a high- Costs accelerate at Most costs are driven Early intervention volume cost predictable by LOS and care can prevent driver1–4 thresholds4–6 intensity6–9 escalation10–15 Large population Stage ≥
Slide 9: +60 Hospitals by end of 2026 – Creating Adoption
+60 Hospitals by end of 2026 – Creating Adoption Expected Development of # of US Hospitals from 2024-2026 +36% 60 • Creating awareness and understanding; to create the future demand 22% 48 44 • NGAL Research Use Only (RUO) & continued focus on 36 the Pediatric segment • Focus on the market in North
Slide 10: Key financials for Q1 2026
Key financials for Q1 2026 Total NGAL revenue of DKK 6 million, an increase of 33% compared to Q1 2025 (48% growth in constant currency) Total revenue for the quarter of DKK 9.4 million, an increase of 23% compared to Q1 2025 (32% growth in constant currency) Adjusted EBITDA loss of DKK 17.9 million
Slide 11: NGAL Sales US continuing strong growth
NGAL Sales US continuing strong growth US NGAL RUO sales (accumulated 12 months rolling at constant exchange rates) 25 +36% 20 19,3 17,8 16,1 15,1 DKKm 15 14,2 13,7 13,0 12,3 11,8 10,1 10,2 10 8,7 5 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Excha
Slide 12: 2026 Financial outlook
2026 Financial outlook Updated after divestment: Total revenue in Total NGAL Adjusted EBITDA 2026 revenue in 2026 loss in 2026 • Expected NGAL revenue growth of 20-50% in 2026 • Lower expected adjusted EBITDA loss in 2026 DKK 38-48 DKK 33-42 DKK 58-68 million (48-58) million (33-42) million (50-60)
Slide 13: Q&A
Q&A